tbuckley/cabot-search huggingface dataset:
OA23.03 Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial
Authors: Glenwood Goss, Manuel Cobo, Shun Lu, Kostas Syrigos, Alessandro Morabito, Istvan Albert, Gabriella Herodek, Samuel Chan, Gyula Ostoros, Veronika Sarosi, Zsolt Kiraly, Deric Savior, Rachael Barton, Francisco Medina, Sundaram Subramanian, Andrea Ardizzoni, Enriqueta Felip, Shirish Gadgeel, Vassilis Georgoulias, James Love, Claudia Bühnemann, Neil Gibson, Eva Ehrnrooth, Jean-Charles Soria, Nicholas Dupuis
Journal: Journal of Thoracic Oncology (2017)
NME-2 Protein Functions as a Tumour Associated Antigen in HLA-A2+ Cells and Is Over Expressed in CML Via a Bcr/Abl Dependent Post Transcriptional Mechanism.
Authors: Sabine Tschiedel, Melanie Adler, Karoline Schubert, Annette Jilo, Enrica Mueller, Song-Y Wang, Michael Cross, Thoralf Lange, Dietger Niederwieser
Journal: Blood (2009)
PUB114 Dose-Response Relationship for Safety and Efficacy Using Stereotactic Body Radiation Therapy for Centrally-Located Non-Small Cell Lung Cancer
Authors: Zhiyong Yuan, Huanhuan Wang, Maobin Meng, Hongqing Zhuang, Yang Dong, Fengtong Li, Jingsheng Wang, Changli Wang, Xishan Hao
Journal: Journal of Thoracic Oncology (2017)
Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults
Authors: Victoria S. Marshe, Malgorzata Maciukiewicz, Soham Rej, Arun K. Tiwari, Etienne Sibille, Daniel M. Blumberger, Jordan F. Karp, Eric J. Lenze, Charles F. Reynolds, James L. Kennedy, Benoit H. Mulsant, Daniel J. Müller
Journal: American Journal of Psychiatry (2017)

The primary objective of this study was to investigate five putatively functional variants of the norepinephrine transporter (SLC6A2, NET) and serotonin transporter (SLC6A4, SERT) genes and remission in depressed older adults treated with venlafaxine. A secondary objective was to analyze 17 other variants in serotonergic system genes (HTR1A, HTR2A, HTR1B, HTR2C, TPH1, TPH2) potentially involved in the mechanism of action of venlafaxine.The sample included 350 adults age 60 or older with DSM-IV-defined major depressive disorder and a score of at least 15 on the Montgomery-Åsberg Depression Rating Scale (MADRS). Participants received protocolized treatment with open-label venlafaxine, up to 300 mg/day for approximately 12 weeks, as part of a three-site clinical trial. Each individual was genotyped for 22 polymorphisms in eight genes, which were tested for association with venlafaxine remission (a MADRS score ≤10) and changes in MADRS score during treatment.After adjusting for multiple comparisons, NET variant rs2242446 (T-182C) was significantly associated with remission (odds ratio=1.66, 95% CI=1.13, 2.42). Individuals with the rs2242446 C/C genotype were more likely to remit (73.1%) than those with either the C/T (51.8%) or the T/T genotype (47.3%). Individuals with the C/C genotype also had a shorter time to remission than those with the C/T or T/T genotypes and had a greater percentage change in MADRS score from baseline to end of treatment (up to week 12).NET rs2242446/T-182C may serve as a biomarker to predict the likelihood of remission with venlafaxine in older adults with major depression. These findings may help to optimize antidepressant outcomes in older adults.
Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program
Authors: Philipp D. le Coutre, Michael O’Dwyer, Tomasz Szczudlo, Richard C. Woodman, Francis J. Giles
Journal: Blood (2008)
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Authors: Arnab Ghosh, Melody Smith, Scott E James, Marco L Davila, Enrico Velardi, Kimon V Argyropoulos, Gertrude Gunset, Fabiana Perna, Fabiana M Kreines, Emily R Levy, Sophie Lieberman, Hillary V Jay, Andrea Z Tuckett, Johannes L Zakrzewski, Lisa Tan, Lauren F Young, Kate Takvorian, Jarrod A Dudakov, Robert R Jenq, Alan M Hanash, Ana Carolina F Motta, George F Murphy, Chen Liu, Andrea Schietinger, Michel Sadelain, Marcel R M van den Brink
Journal: Nature Medicine (2017)
P1.03-039 Is It Necessary to Repeat Lung Cancer Screening with Low-Dose CT(LDCT) in Female Never Smokers?
Authors: Hyae Young Kim, Kyu-Won Jung, Kun Young Lim, Soo Hyun Lee, Jae Kwan Jun, Byung-Ho Nam, Jeongseon Kim, Bin Hwangbo, Yoo Sun Choi, Hyemi Jo, Jin Soo Lee
Journal: Journal of Thoracic Oncology (2017)
P75 Patient experience of non-invasive ventilation: a qualitative study
Authors: N Goldman, L Richardson, S Blakey, L Staveacre, SAA Bloch
Journal: Thorax (2016)

<h3>Introduction</h3> Non-invasive ventilation (NIV) is an effective treatment for acute type 2 respiratory failure, often avoiding intubation and improving mortality. However many patients struggle to tolerate NIV. There is limited understanding of patients’ or their relatives/carers subjective experience of NIV. As good patient experience is increasingly recognised to reflect high-quality care we conducted an in-depth experience-based questionnaire aiming to identify key concerns of patients, and their relatives/carers, treated with NIV, which would reflect potential targets for service improvement. <h3>Method</h3> In a qualitative, exploratory study patients started acutely on NIV were identified. Patients and relatives/carers completed a questionnaire with both free text and Likert style responses. Data were analysed using thematic analysis. <h3>Results</h3> 20 questionnaires were completed (15 patients, 5 relatives). From the responses we identified key themes. Emotional responses were positive and negative. Positively - all patients and carers felt that NIV had helped. However whilst <i>all</i> carers would wish their relatives to have NIV again, 2 of the patients felt they would not. Negative emotional responses were related to fear and anxiety of NIV. A significant theme emerged surrounding the physical discomfort of NIV. Descriptions of NIV are represented in Figure 1. Patients and relatives identified that negative feelings were partly due to lack of understanding. Only 9 patients felt that they were involved in decision making and only 6 felt that NIV had been adequately explained. 11 patients and all relatives felt that written information would be beneficial. Finally a further theme described different levels of competence between staff and across wards and the varying degrees of feeling safe that this created. <h3>Conclusion</h3> This study enabled us to identify key areas to address when considering quality improvement for NIV service delivery. Whilst our sample size is small, and biassed towards survivors, the themes are strong and add significantly to the available literature. Some aspects of NIV are non-modifiable however focus on patient involvement and experience to provide high-quality care may facilitate improved experience and outcomes. We aim to address these points by expanding on this work in an experience-based co-designed project, funded by CLAHRC.
MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates
Authors: Vassiliki Papadimitrakopoulou, Mary Redman, David R. Gandara, Fred R. Hirsch, Philipp Mack, Hossein Borghaei, Corey Langer, James Wade, Martin Edelman, Kathy Albain, Primo Lara, Charu Aggarwal, Mark Socinski, Scott Gettinger, Lyudmila Bazhenova, Shakun Malik, Vincent Miller, Shannon Mcdonough, Ellen V. Sigal, Karen Kelly, Roy Herbst
Journal: Journal of Thoracic Oncology (2017)
P3.02b-060 Comparative Analysis of the Efficacy of Three 1st/2nd Generation EGFR-TKIs for EGFR Mutated NSCLC in Clinical Practice
Authors: Kentaro Ito, Hataji Osamu, Yuta Suzuki, Saiki Haruko, Tadashi Sakaguchi, Kosuke Hayashi, Yoichi Nishii, Fumiaki Watanabe, Atsushi Fijiwara, Masamichi Yoshida, Tetsu Kobayashi, Esteban Gabazza, Osamu Taguchi
Journal: Journal of Thoracic Oncology (2017)
P1.02-022 Establishing Reflex NGS Testing in NSCLC in a Regional Network of County Hospitals in Central Sweden
Authors: Johan Isaksson, Linda Willén, Linnea La Fleur, Stephanié Mindus, Magnus Sundstrom, Eva Brandén, Hirsh Koyi, Martin Sandelin, Kristina Lamberg, Patrick Micke, Lotte Moens, Gabriel Lundberg, Johan Botling
Journal: Journal of Thoracic Oncology (2017)
P3.02b-096 Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results
Authors: Caicun Zhou, Mengzhao Wang, Ying Cheng, Yuan Chen, Yanqui Zhao, Yuan-Kai Shi, He-Long Zhang, Myung-Ju Ahn, Yajuan Chen, Jia Wang, Mireille Cantarini, Yi Long Wu
Journal: Journal of Thoracic Oncology (2017)
P142 The distribution of blood eosinophil count in a copd clinical trials database: comparing the uk with the rest of the world
Authors: E Hilton, C Compton, D Midwinter, N Barnes
Journal: Thorax (2016)

<h3>Introduction</h3> There is accumulating evidence that blood eosinophil count may have predictive value for those individuals with COPD who are more likely to respond to an inhaled corticosteroid in terms of exacerbation reduction and there is evidence that higher blood eosinophil count can also have some predictive value for those at risk of exacerbations. Blood eosinophil counts are known to be raised in a number of conditions including allergies and parasitic or fungal infections. It is therefore possible that the blood eosinophil count would vary between countries and thus influence their predictive value. We have investigated the distribution of blood eosinophil counts in the UK in comparison with blood eosinophil counts worldwide from data in the GSK clinical trials database. <h3>Methods</h3> In this post-hoc analysis, the following criteria were used to select studies for consistency with analyses conducted to examine the effects of inhaled corticosteroids on outcomes: global, randomised, double-blind, parallel-group clinical trials in COPD of at least 24 weeks’ duration that included any of fluticasone propionate (FP), fluticasone furoate (FF), salmeterol/FP or FF/vilanterol (VI) as a randomised study drug and a non-steroid-containing arm and for which subjects had a pre-randomisation blood sample taken for eosinophils.<sup>1,2</sup> Individual subjects’ pre-randomisation eosinophil counts from countries that recruited at least 100 subjects across all trials were pooled to form the global sample (Argentina, Australia, Canada, Chile, Czech Republic, Denmark, Estonia, France, Germany, Greece, Italy, Korea, Lithuania, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russia, Slovakia, South Africa, Spain, Sweden, United Kingdom, United States). Individual subjects’ pre-randomisation eosinophil counts for subjects in the UK were pooled to form the UK sample. An empirical cumulative distribution function (CDF) for the UK sample was overlaid on an empirical CDF plot for the global sample. <h3>Results</h3> The blood eosinophil count in COPD patients included in these trials in the UK is very similar to that worldwide (Figure). <h3>Conclusions</h3> This suggests that blood eosinophil count could be used in the UK to help predict response to inhaled corticosteroids in COPD. <h3>References</h3> Pavord. <i>Lancet Respir Med</i> 2016, in press. Pascoe. <i>Lancet Respir Med</i> 2015.
Intercommunication Between C-Myc and PTEN in the Regulation of Hematopoietic Stem Cell-Niche Interactions and Hematopoietic Progenitor Cell Lineage Commitment.
Authors: Yinshi Guo, Chao Niu, Peter Breslin, Shubin Zhang, Wei Wei, Minghui Tang, Jiwang Zhang
Journal: Blood (2008)
P183 Burden of illness in school-aged patients with cystic fibrosis (CF) in the united states
Authors: J Rubin, M Bonafede, S Sikirica, B Limone, N Adolph, M Konstan
Journal: Thorax (2016)

<h3>Background and objectives</h3> The CF disease burden among school-aged children is not well understood. We sought to describe this burden in patients with CF aged 6–17 years in the United States by comparing their healthcare resource utilisation (HCRU) to that of demographically similar controls without CF. <h3>Methods</h3> This retrospective study used administrative claims from the Truven MarketScan Medicaid Multi-State (CAID) and Commercial (COMM) databases. Patients with CF aged 6–17 years were identified as having ≥1 inpatient (IP) or ≥2 outpatient (OP) medical claims ≥30 days apart with primary diagnosis of CF (ICD-9-CM: 277.0x) between 2010 and 2014. Other inclusion criteria were ≥12 months of continuous medical and pharmacy coverage and ≥1 CF-related healthcare encounter during the most recent year of data. Patients were matched 1:3 to non-CF controls by age, gender, race (CAID cohort), geographic region (COMM cohort), insurance plan type and enrollment (calendar year). IP admissions, OP visits and medication use from the most recent year of data (2010–2014) were compared between patients and controls, overall and by age group (6–11 and 12–17 years), using bivariate statistics; chi-square tests were used for categorical variables and <i>t</i> tests and ANOVA for continuous variables. <h3>Results</h3> The CAID cohort included 1264 patients with CF and the COMM cohort 2400; all were matched 1:3 to controls (mean [SD] age of patients and controls: CAID, 11.4 [3.5]; COMM, 11.9 [3.5]). Annual hospitalisation rates were 22-fold (CAID) to 32-fold (COMM) higher in the CF cohorts, with lengths of stay nearly twice that of matched controls (<b>Table</b>). Annual OP visit rates were 3.1-fold (CAID) and 3.5-fold (COMM) higher in the CF cohorts, and patients filled 5 times as many unique medications and 10 times as many total prescriptions per year as controls. While patients with CF aged 12–17 years generally had higher HCRU than those aged 6–11, trends and magnitude difference vs controls within each age group were similar. <h3>Conclusion</h3> HCRU was higher in patients with CF aged 6–17 years than in demographically similar children without CF, illustrating significant disease burden and a need for better treatment options for this population. Sponsored by Vertex Pharmaceuticals Incorporated Please refer to page A272 for declarations of interest in relation to abstract P183.
Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95.
Authors: Anja Möricke, Richard Ratei, Wolf-Dieter Ludwig, Jochen Harbott, Arndt Borkhardt, Susanne Viehmann, Martin Zimmermann, Helmut Gadner, Hansjörg Riehm, Martin Schrappe
Journal: Blood (2004)
Feasibility pilot of attenuated maintenance chemotherapy for adolescents and adults with newly diagnosed localized medulloblastoma and other primitive neuroectodermal tumors.
Authors: J. N. Dagri, A. Evans, J. Torkildson, J. Portnow, L. S. Ashby, B. Zakotnik, R. J. Brown, G. Dhall, J. L. Finlay
Journal: Journal of Clinical Oncology (2011)

2081 Background: Newly-diagnosed adolescents and adults with medulloblastoma experience substantial toxicities with “standard” maintenance chemotherapy regimens including CCNU, cisplatin and vincristine. We evaluated an attenuated maintenance chemotherapy regimen targeting adolescents and adults. Methods: Eleven patients with newly-diagnosed medulloblastoma and 1 suprasellar atypical teratoid/rhabdoid tumor (AT/RT) were treated between 2004 and 2010. Eight patients were between 17 and 50 years old. Nine were female. Eleven received 2340cGy craniospinal irradiation, 1 AT/RT 3600cGy, all with standard posterior fossa or tumor bed boosts. Ten patients received weekly vincristine x 6 (1.5mg/M2, max. 2mg) during irradiation. Maintenance chemotherapy was initiated 4-6 weeks following irradiation: Cycle A: vincristine (days 1, 8), oral temozolomide (150mg/m2 days 1-5) and oral etoposide (50mg/M2 days 1-21), Cycle B: vincristine (days 1, 8), carboplatin day 1 (560mg/M2). Cycle C: vincristine (days 1, 8), cyclophosphamide (600mg/M2 on days 1 and 2). Cycles A, B and C were repeated for 9 total cycles. Retrospective collection of toxicity and outcome data was approved by institutional IRBs for all patients. Results: A total of 87 cycles were administered. Grades III/IV neutropenia occurred in 71% cycles, anemia in 37% cycles and thrombocytopenia in 29% cycles. Grades 3/4 transaminitis occurred in 8% cycles. There were 5 grade 2 reports of anorexia, 1 grade 3 sensory and 4 grade 3 motor neuropathies and one grade 3 hypocalcemia. No grades 1-IV ototoxicities or nephrotoxicities were observed. No grades 3/4 weight loss were observed. Two patients had single hospitalizations for chemotherapy-related toxicities (1 and 13 days’ duration). After 3 years median follow-up, no patient with medulloblastoma relapsed; the ATRT patient recurred 24 months from diagnosis. Conclusions: This attenuated maintenance chemotherapy regimen was well tolerated by adolescents and adults. A prospective North American clinical trial is planned for adult medulloblastoma/PNET to determine the efficacy of this regimen.
Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).
Authors: Aref Al-Kali, Dan Jones, Jorge Cortes, Stefan Faderl, Xue Ao, Guillermo Garcia-Manero, Gautam Borthakur, Marina Konopleva, Mark Brandt, Michael Andreeff, Hagop Kantarjian, Farhad Ravandi
Journal: Blood (2009)
Annals Graphic Medicine - Breach of Confidentiality
Authors: Caroline Shooner
Journal: Annals of Internal Medicine (2017)

Web Exclusives3 January 2017Annals Graphic Medicine - Breach of ConfidentialityFREECaroline Shooner, MDCaroline Shooner, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G16-0019 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G16-0019.Author Information: Dr. Shooner is a general practitioner on the remote archipelago of Haida Gwaii, in western Canada. Her cartoons (www.theboondocs.org) explore the comic side of small town medicine.Corresponding Author: Caroline Shooner, MD, PO Box 669, 3110, 2nd Avenue, Queen Charlotte, British Columbia V0T 1S0, Canada; e-mail, [email protected]com.Author Contributions: Conception and design: C. Shooner.Final approval of the article: C. Shooner. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 3 January 2017Volume 166, Issue 1Page: W1-W2KeywordsDisclosureHealth care ePublished: 3 January 2017 Issue Published: 3 January 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Antibiotic Therapy of H. Pylori Negative Gastric MALT Lymphoma
Authors: Seung Tae Lee, Purnima Teegavarupu, Anusha Karri, Saswatha Anireddy, Fredrick B. Hagemeister, Jorge E. Romaguera, Luis Fayad, Maria A. Rodriguez, Felipe Samaniego, Nathan Fowler, Yasuhiro Oki, Francesco Turturro, Jason R. Westin, Larry W Kwak, Bouthaina S. Dabaja, Lei Feng, R Eric Davis, Sattva S Neelapu
Journal: Blood (2014)
HDR brachytherapy in advanced esophageal cancer: Analysis of the palliation of dysphagia in 108 patients.
Authors: R. Grazziotin, M. L. Reisner, A. A. Rosa, T. M. Carneiro, I. M. Veras, M. A. Ferreira, F. M. Vieira, C. G. M. Ferreira, C. M. Viegas, C. M. Araujo
Journal: Journal of Clinical Oncology (2011)

e14599 Background: Most of the esophageal cancer patients are inoperable at presentation. Dysphagia is one of the main symptoms and patient’s quality of life is an important aspect of the treatment. The purpose of this retrospective study was to estimate the improvement in the palliation of dysphagia and the complication rate of the HDR brachytherapy. Methods: In the period between August 1997 and July 2008, 108 patients with advanced esophageal cancer, were submitted to 3 sessions of HDR brachytherapy, 5Gy each. Patients with cervical esophagus were also subjected to brachytherapy.Patients with tracheoesophagicfistula visible through the bronchoscopy were considered ineligible. Dysphagia was divided in 4 grades: absent (0), solid (1), semisolids (2), liquid (3). The improvement was measured in a scale of points;1 point corresponding to an improvement in 1 grade of dysfaghia and 2 or 3 points corresponding to an improvement of 2 or 3 grades. Results: After 8 weeks after brachytherapy, dysphagia was relieved in 36 % of the patients, remained stable in 42% and worsened in 22% of the cases. An improvement of 1 point was observed in 21% patients, with an improvement of 2 and 3 points in 10.5% and 4.7 % of patients respectively. Complete response was observed in 21.2%, greater than 50% response in 18.5%, less than 50% response in 12% and disease progression in 47.2% of the patients, assessed by endoscopy. Stenosis was observed in 39.8 % of patients, with 6.5% presenting bleeding, and 7.4% presenting fistula. Esophageal dilatation was performed in 29 % of the cases and prosthesis was implanted in 11.5 %. An analysis comparing the complication rate with the location of the tumor (upper, middle and lower esophagus) showed the presence of stenosis in 46.1%, 37.8% and 42.8% of the patients; bleeding in 15.3%, 4% and 9.5%; and late fistula in 0%, 9.4% and 4.7% respectively. Conclusions: In patients with esophageal advanced disease treated at a major center of a developing country, it was demonstrated that brachytherapy is an effective treatment for the palliation of malignant dysphagia. Brachytherapy in upper esophagus is a feasible treatment, since it showed equivalent complication rate compared to middle and lower locations.
Relationship of body mass index to the intrinsic subtypes of breast cancer.
Authors: C. A. Santa-Maria, Y. D. Zhao, N. Ketring, I. Rodriguez, A. Condren, D. Euhus
Journal: Journal of Clinical Oncology (2011)

1529 Background: Increased body mass index (BMI) has traditionally been associated with an increased risk for hormone receptor positive breast cancer in postmenopausal women, but recent studies have also linked it to aggressive phenotype breast cancers in premenopausal women. A better understanding of the relationship between BMI and specific intrinsic subtypes of breast cancer can contribute directly to the design and development of cancer prevention and treatment trials that address energy balance and obesity. Purpose: To evaluate the relationship between BMI and the intrinsic subtypes of breast cancer. Methods: From 740 patients with primary invasive breast cancer diagnosed during 2008 and 2009, BMI at time of diagnosis was ascertainable for 693 patients. BMI was categorized according to the World Health Organization classification and intrinsic subtypes were approximated by immunohistochemistry using ER, PR, HER2/neu, CK 5/6, EGFR, and Ki67 as previously described and validated (Clin Cancer Res, 2008 and J Natl Cancer Inst, 2009). Results: Distribution of the sample set by BMI included 15 (2.2%) underweight, 190 (27.4%) ideal weight, 202 (29.1%) overweight, and 286 (41.3%) obese patients. Increasing BMI was associated with an increasing proportion of luminal B cases (28.6%, 27.9%, 33.3% and 38.9% for underweight, ideal weight, overweight and obese women respectively, p= 0.02). This was significant for premenopausal (p=0.004) but not postmenopausal women (p=0.4). Increasing BMI was also found to be associated with higher tumor grades (p= 0.03), but not with triple negative or HER2 subtypes. Conclusions: Increased BMI is associated with a unique breast cancer pathobiology favoring the development of high grade and luminal B breast cancers, especially in premenopausal women. The success of clinical trials targeting overweight and obese women to improve treatment response and outcome may be improved by focusing on this subtype.